Normally, the company would not see any results until all patients had been followed for the entire length of the trial, but Tularik will take a look at a small percentage of these patients while the clinical trials are still ongoing in order to make sure that there are no unexpected problems with the drug's safety or efficacy.
FORBES: Magazine Article